ArticleBMC cancer2026
Cardiotoxicity perspective on the concurrent use of anti-HER2 agents and hypofractionated versus conventional fractionated locoregional radiotherapy in breast cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHER2-targeted therapies (trastuzumab, T-DM1) improve outcomes in HER2-positive breast cancer but are associated with cardiotoxicity. Radiotherapy also carries cardiac risks, although hypofractionated schedules have not shown increased toxicity. This study evaluated the cardiac safety of concomitant HER2-targeted therapies with different radiotherapy regimens.
methodsThis retrospective study included 148 patients with HER2-positive breast cancer who underwent surgical resection following neoadjuvant chemotherapy between 2012 and 2023. All patients subsequently received adjuvant radiotherapy and anti-HER2 therapy. To evaluate the potential cardiotoxicity of concomitant treatment, patients were stratified according to radiotherapy fractionation schedules. Echocardiographic assessment was performed at baseline and every three months during the entire treatment period.
resultsAmong the 148 patients, 70 (47.3%) received hypofractionated radiotherapy and 78 (52.7%) received conventional fractionation. Adjuvant trastuzumab was administered to 132 (89.2%) patients, while 16 (10.8%) received T-DM1, with a similar distribution across the two radiotherapy groups. The median follow-up was 44 months (22-150). No significant association was observed between radiotherapy fractionation or the type of adjuvant anti-HER2 therapy and cardiotoxicity. However, smoking, internal mammary node radiotherapy, higher mean heart dose, and higher heart V10 and V20 were significantly associated with increased cardiotoxicity.
conclusionConcurrent anti-HER2 therapies with breast/chest wall and regional nodal irradiation, including both conventional and hypofractionated schedules, is feasible and generally safe, though cardiac-sparing techniques and careful management of patients at higher risk, including those receiving internal mammary nodal irradiation or with a history of smoking, are important to minimize cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.